Abstract
In this study, we elucidated the potential of recombinant adeno-associated virus type-2 (rAAV-2) vectors for lung cancer gene therapy. Cell lines of the three major histological subtypes of non-small cell lung cancer (NSCLC) were highly susceptible for rAAV-2 showing transduction rates between 63.4 and 98.9%. In contrast, cell lines of small cell carcinomas were resistant to rAAV-2 infection. For restoration of p53 function in p53 deficient NSCLC, a rAAV-2 vector was constructed containing wt p53 cDNA. Following transduction with rAAV-p53, cell growth of all NSCLC cell lines was significantly reduced in a dose-dependent manner between 44 and 71.7% in comparison with rAAV-GFP transduced cells. The reduction of tumor cell growth was associated with increased apoptosis. Adding cisplatin to rAAV-p53-infected cells led to a significant growth inhibition between 81 and 91% indicating a synergistic effect between cisplatin and rAAV-p53. Interestingly, the tumor cells surviving cisplatin and rAAV-p53 treatment were inhibited in their ability to form colonies as reflected by a reduction of colony growth between 57 and 90.4%. In conclusion, rAAV-2 vectors exhibit a strong tropism for NSCLC. Successful inhibition of tumor cell growth following transduction with a rAAV-p53 vector underlines the potential role of rAAV-2 in cancer gene therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Landis SH, Murray T, Bolden S, Wingo PA .Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8–31.
Wang X, Liu Y, Chow LS, et al. Cisplatin-induced p53-independent growth arrest and cell death in cancer cells. Int J Oncol. 1999;15:1097–1102.
Lowe SW, Ruley HE, Jacks T, Housman DE . p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957–967.
Rusch V, Klimstra D, Venkatraman E, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995;55:5038–5042.
Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 1993;53:1–4.
Horster A, Teichmann B, Hormes R, Grimm D, Kleinschmidt J, Sczakiel G . Recombinant AAV-2 harboring gfp-antisense/ribozyme fusion sequences monitor transduction, gene expression, and show anti-HIV-1 efficacy. Gene Therapy. 1999;6:1231–1238.
Samulski RJ, Chang LS, Shenk T . Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol. 1989;63:3822–3828.
Grimm D, Kern A, Rittner K, Kleinschmidt JA . Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther. 1998;9:2745–2760.
Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy. 1999;6:973–985.
Rohr UP, Kronenwett R, Grimm D, Kleinschmidt J, Haas R . Primary human cells differ in their susceptibility to rAAV-2-mediated gene transfer and duration of reporter gene expression. J Virol Methods. 2002;105:265–275.
Rohr UP, Wulf MA, Stahn S, Steidl U, Haas R, Kronenwett R . Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J Virol Methods. 2002;106:81–88.
Horio Y, Hasegawa Y, Sekido Y, Takahashi M, Roth JA, Shimokata K . Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells. Cancer Gene Ther. 2000;7:537–544.
Kronenwett R, Graf T, Nedbal W, et al. Inhibition of angiogenesis in vitro by alphav integrin-directed antisense oligonucleotides. Cancer Gene Ther. 2002;9:587–596.
Summerford C, Bartlett JS, Samulski RJ . AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med. 1999;5:78–82.
Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A . Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med. 1999;5:71–77.
Hollon T . Researchers and regulators reflect on first gene therapy death. Nat Med. 2000;6:6.
Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24:257–261.
Smith J, Herrero R, Erles K, et al. Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia. Int J Cancer. 2001;94:520–526.
Coker AL, Russell RB, Bond SM, et al. Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia. Exp Mol Pathol. 2001;70:83–89.
Eisold S, Dihlmann S, Linnebacher M, et al. Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2. Int J Cancer. 2002;100:606–614.
Schwarzbach MH, Eisold S, Burguete T, et al. Sensitization of sarcoma cells to doxorubicin treatment by concomitant wild-type adeno-associated virus type 2 (AAV-2) infection. Int J Oncol. 2002;20:1211–1218.
Duverger V, Sartorius U, Klein-Bauernschmitt P, Krammer PH, Schlehofer JR . Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2. Int J Cancer. 2002;97:706–712.
Levine AJ . p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331.
Koty PP, Zhang H, Franklin WA, Yousem SA, Landreneau R, Levitt ML . In vivo expression of p53 and Bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions. Lung Cancer. 2002;35:155–163.
Spitz FR, Nguyen D, Skibber JM, Cusack J, Roth JA, Cristiano RJ . In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res. 1996;16:3415–3422.
Bouvet M, Bold RJ, Lee J, et al. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol. 1998;5:681–688.
Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE . Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Therapy. 1997; 4: 675–682.
Acknowledgements
This work was supported by the Leukämie Liga Duesseldorf.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rohr, UP., Wulf, MA., Stahn, S. et al. Non-small lung cancer cells are prime targets for p53 gene transfer mediated by a recombinant adeno-associated virus type-2 vector. Cancer Gene Ther 10, 898–906 (2003). https://doi.org/10.1038/sj.cgt.7700643
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700643
Keywords
This article is cited by
-
Nisin ZP, an Antimicrobial Peptide, Induces Cell Death and Inhibits Non-Small Cell Lung Cancer (NSCLC) Progression in vitro in 2D and 3D Cell Culture
Pharmaceutical Research (2022)
-
Comparative analysis of the transduction efficiency of five adeno associated virus serotypes and VSV-G pseudotype lentiviral vector in lung cancer cells
Virology Journal (2013)
-
RNA Aptamer-targeted Inhibition of NF-κB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin
Molecular Therapy (2008)
-
The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells
Cancer Gene Therapy (2007)